Cargando…

Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis

Aberrant somatic hypermutation (aSHM) can target proto-oncogenes and drive oncogenesis. In mantle cell lymphoma (MCL), CCND1 is targeted by aSHM in the non-nodal subtype (nnMCL), giving rise to exon1 encoded mutant proteins like E36K, Y44D, and C47S that contribute to lymphomagenesis by virtue of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Heiko, Walter, Wencke, Hutter, Stephan, Nadarajah, Niroshan, Meggendorfer, Manja, Kern, Wolfgang, Haferlach, Torsten, Haferlach, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113931/ https://www.ncbi.nlm.nih.gov/pubmed/35145272 http://dx.doi.org/10.1038/s41417-022-00428-7

Ejemplares similares

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

“Somatic” and “pathogenic” - is the classification strategy applicable in times of large-scale sequencing?
por: Baer, Constance, et al.
Publicado: (2019)

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
por: Baer, Constance, et al.
Publicado: (2023)

Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations
por: Höllein, Alexander, et al.
Publicado: (2019)

Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA
por: Parida, Laxmi, et al.
Publicado: (2019)

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
por: Cappelli, Luca Vincenzo, et al.
Publicado: (2021)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia
por: Walter, Wencke, et al.
Publicado: (2021)

S161: UBA1 NON-M41 VARIANTS ARE MORE AGGRESSIVE THAN UBA1 M41 VARIANTS IN THEIR HEMATOLOGICAL MANIFESTATIONS.
por: Sakuma, Maki, et al.
Publicado: (2023)

P690: IDENTIFICATION OF CLINICALLY RELEVANT VARIANT-LEVEL SEX-BIAS IN SF3B1 K700/K666 AND IDH2 R140/R172
por: Sakuma, Maki, et al.
Publicado: (2023)

How artificial intelligence might disrupt diagnostics in hematology in the near future
por: Walter, Wencke, et al.
Publicado: (2021)

Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
por: Meggendorfer, Manja, et al.
Publicado: (2017)

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

MDS subclassification—do we still have to count blasts?
por: Huber, Sandra, et al.
Publicado: (2023)

Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia
por: Baer, Constance, et al.
Publicado: (2021)

P814: ANALYSIS OF TP53 ALTERATIONS BY WGS REVEALS BIALLELIC 17P DELETIONS IN MULTIPLE MYELOMA
por: Truger, Marietta, et al.
Publicado: (2023)

P533: A FULLY AUTOMATED SUPERVISED AI-BASED CELL CLASSIFIER TO ACCURATELY FLAG PATHOLOGICAL SIGNATURE CELLS IN 28,285 REAL-WORLD BLOOD SMEARS
por: Maier, Christopher, et al.
Publicado: (2023)

Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies
por: Sakuma, Maki, et al.
Publicado: (2023)

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis
por: Huber, Sandra, et al.
Publicado: (2022)

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase
por: Huber, Sandra, et al.
Publicado: (2022)

P689: CLASSIFICATION OF MDS AND AML BASED SOLELY ON GENETICS OMITTING BLAST COUNTING – A WAY TO RESOLVE THE DISCREPANCIES BETWEEN CLASSIFICATIONS ACCORDING TO WHO AND ICC?
por: Haferlach, Claudia, et al.
Publicado: (2023)

Complex Landscape of Alternative Splicing in Myeloid Neoplasms
por: Hershberger, Courtney E., et al.
Publicado: (2020)

Correction: How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing
por: Müller, Janine, et al.
Publicado: (2022)

How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing
por: Müller, Janine, et al.
Publicado: (2022)

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022)

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts
por: Huber, Sandra, et al.
Publicado: (2022)

AML classification in the year 2023: How to avoid a Babylonian confusion of languages
por: Huber, Sandra, et al.
Publicado: (2023)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
por: Huber, Sandra, et al.
Publicado: (2023)

P708: HIGH MUTATIONAL CONCORDANCE IN PAIRED BONE MARROW AND PERIPHERAL BLOOD SAMPLES IN PATIENTS WITH CONFIRMED OR SUSPECTED MYELODYSPLASTIC NEOPLASM
por: Wossidlo, Natalie, et al.
Publicado: (2023)

SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
por: van der Werf, Inge, et al.
Publicado: (2021)

Recurrent targets of aberrant somatic hypermutation in lymphoma
por: Khodabakhshi, Alireza Hadj, et al.
Publicado: (2012)

P1213: ARTIFICIAL INTELLIGENCE TO PREDICT MEDICAL DIAGNOSIS FROM FLOW CYTOMETRIC RAW DATA IN MATURE B-CELL AND T-CELL NEOPLASMS, AML, ALL, MDS AND MULTIPLE MYELOMA
por: Müller, Martha-Lena, et al.
Publicado: (2023)

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia
por: Weber, S, et al.
Publicado: (2014)

Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
por: Adema, Vera, et al.
Publicado: (2022)

The new provisional WHO entity ‘RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia
por: Haferlach, T, et al.
Publicado: (2016)

Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2021)

CD5-negative Blastoid Variant Mantle Cell Lymphoma with Complex CCND1/IGH and MYC Aberrations
por: Seok, Yoonmi, et al.
Publicado: (2012)

Tandem Substitutions in Somatic Hypermutation
por: Sepúlveda-Yáñez, Julieta H., et al.
Publicado: (2022)

Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma
por: Grossmann, V, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dhhfuve8i0chunhr7aj9ahnfrh